Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. In July 2010, Momentaâs lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOXÂŽ (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily GlatopaÂŽ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONEÂŽ 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRAÂŽ (adalimumab), a biosimilar version of ORENCIAÂŽ (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications. Source
No articles found.
Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai...
Cellect Biotechnology Ltd. was founded in 2011 ...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...
BrainsWay is an industry leader in the field of...
Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...
Celyad is a biopharmaceutical company, speciali...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Join the National Investor Network and get the latest information with your interests in mind.